<?xml version="1.0" encoding="UTF-8"?>
<p>In 2016, the first clinical experience of using remdesivir against Ebola virus in human was reported.
 <xref rid="cit0024" ref-type="bibr">24</xref> Ebola meningoencephalitis was diagnosed in a female nurse by detection of Ebola virus RNA in the plasma and cerebrospinal fluid. The patient was successfully treated by administration of corticosteroids and remdesivir for 2 weeks (once-daily administration of 150 mg over 2 h for 2 days, and then daily using of 225 mg for 12 days). In spite of a temporary increase in the levels of the enzyme amylase in serum, any serious adverse event was not observed.
 <xref rid="cit0024" ref-type="bibr">24</xref>
</p>
